$UBX
Unity Biotechnology, Inc.

2024 Q2 Form 10-K Financial Statement

#000095017024044237 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.285M $18.77M
YoY Change -18.84% -10.42%
% of Gross Profit
Research & Development $3.463M $2.833M $19.70M
YoY Change -46.96% -67.2% -46.56%
% of Gross Profit
Depreciation & Amortization $221.0K $232.0K $1.182M
YoY Change -29.62% -43.28% -45.78%
% of Gross Profit
Operating Expenses $6.979M $7.118M $38.47M
YoY Change -41.66% -48.85% -33.46%
Operating Profit -$6.979M -$44.67M
YoY Change -41.66% -22.42%
Interest Expense $515.0K $524.0K $422.0K
YoY Change -47.4% -381.72% -88.14%
% of Operating Profit
Other Income/Expense, Net -$61.00K $5.096M $4.885M
YoY Change -11.59% -7821.21% -28835.29%
Pretax Income -$1.498M -$39.86M
YoY Change -89.43% -33.49%
Income Tax
% Of Pretax Income
Net Earnings -$5.279M -$1.498M -$39.86M
YoY Change -56.75% -89.43% -33.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31 -$2.70
Diluted Earnings Per Share -$0.31 -$0.10 -$2.70
COMMON SHARES
Basic Shares Outstanding 16.79M 14.62M 14.77M
Diluted Shares Outstanding 16.82M 14.77M

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.98M $43.20M $43.20M
YoY Change -50.81% -54.43% -54.43%
Cash & Equivalents $7.584M $19.80M $19.80M
Short-Term Investments $26.40M $23.40M $23.40M
Other Short-Term Assets $1.862M $3.404M $3.404M
YoY Change -51.94% 95.63% 95.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.85M $46.61M $46.61M
YoY Change -50.87% -51.72% -51.72%
LONG-TERM ASSETS
Property, Plant & Equipment $4.630M $18.06M $18.06M
YoY Change -81.66% 130.84% -32.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $1.022M $1.022M
YoY Change -72.25% 1865.38% 7.81%
Total Long-Term Assets $17.68M $19.09M $19.09M
YoY Change -36.97% -31.39% -31.39%
TOTAL ASSETS
Total Short-Term Assets $35.85M $46.61M $46.61M
Total Long-Term Assets $17.68M $19.09M $19.09M
Total Assets $53.52M $65.69M $65.69M
YoY Change -47.01% -47.17% -47.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.456M $1.380M $1.380M
YoY Change 0.48% -22.91% -22.91%
Accrued Expenses $5.977M $6.460M $6.460M
YoY Change -15.45% 21.11% -22.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $8.818M $7.840M $7.840M
YoY Change -60.32% -60.04% -60.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $24.95M $29.45M $29.45M
YoY Change -1.37% 9.12%
Total Long-Term Liabilities $24.95M $29.45M $29.45M
YoY Change -15.08% 170.43% -22.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.818M $7.840M $7.840M
Total Long-Term Liabilities $24.95M $29.45M $29.45M
Total Liabilities $33.77M $37.29M $37.29M
YoY Change -34.56% -35.15% -35.15%
SHAREHOLDERS EQUITY
Retained Earnings -$495.4M -$484.4M
YoY Change 2.57% 5.3%
Common Stock $515.2M $512.8M
YoY Change -3.26% -2.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.75M $28.40M $28.40M
YoY Change
Total Liabilities & Shareholders Equity $53.52M $65.69M $65.69M
YoY Change -47.01% -47.17% -47.17%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$5.279M -$1.498M -$39.86M
YoY Change -56.75% -89.43% -33.49%
Depreciation, Depletion And Amortization $221.0K $232.0K $1.182M
YoY Change -29.62% -43.28% -45.78%
Cash From Operating Activities -$4.584M -$7.578M -$37.09M
YoY Change -58.64% -26.9% -27.28%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $11.00K
YoY Change -97.3% -88.54%
Acquisitions
YoY Change
Other Investing Activities $4.670M $15.12M $60.51M
YoY Change -52.61% -9915.58% -347.48%
Cash From Investing Activities $4.670M $15.11M $60.50M
YoY Change -52.61% -8013.61% -346.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.223M
YoY Change
Debt Paid & Issued, Net $20.00M
YoY Change
Cash From Financing Activities 68.00K 4.390M -16.34M
YoY Change -102.59% 2528.74% -129.79%
NET CHANGE
Cash From Operating Activities -4.584M -7.578M -37.09M
Cash From Investing Activities 4.670M 15.11M 60.50M
Cash From Financing Activities 68.00K 4.390M -16.34M
Net Change In Cash 154.0K 11.93M 7.067M
YoY Change -104.0% -214.79% -134.11%
FREE CASH FLOW
Cash From Operating Activities -$4.584M -$7.578M -$37.09M
Capital Expenditures $1.000K $11.00K
Free Cash Flow -$7.579M -$37.10M
YoY Change -27.15% -27.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001463361
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38470
CY2023 dei Entity Registrant Name
EntityRegistrantName
Unity Biotechnology, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4726035
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
285 East Grand Ave.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
416-1192
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2023 dei Trading Symbol
TradingSymbol
UBX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
true
CY2023 dei Document Fin Stmt Restatement Recovery Analysis Flag
DocumentFinStmtRestatementRecoveryAnalysisFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
34108688
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16786647
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Mateo, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19803000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12736000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
23398000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82059000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3404000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1740000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
46605000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96535000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5082000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7825000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12981000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19042000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-251000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2023Q4 us-gaap Assets
Assets
65690000
CY2022Q4 us-gaap Assets
Assets
124350000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1380000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1790000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1841000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3020000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4619000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5334000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9476000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7840000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19620000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23539000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26991000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10891000
CY2023Q4 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
5913000
CY2022Q4 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
10764000
CY2023Q4 us-gaap Liabilities
Liabilities
37292000
CY2022Q4 us-gaap Liabilities
Liabilities
68266000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16784969
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16784969
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14215302
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14215302
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
512773000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
500827000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-484353000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444493000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28398000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56084000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65690000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124350000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4784000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20099000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36859000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38393000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18966000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20949000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23056000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5602000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Operating Expenses
OperatingExpenses
44667000
CY2022 us-gaap Operating Expenses
OperatingExpenses
57808000
CY2021 us-gaap Operating Expenses
OperatingExpenses
61449000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-44667000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-57572000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-56665000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2874000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1220000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
100000
CY2023 us-gaap Interest Expense
InterestExpense
2452000
CY2022 us-gaap Interest Expense
InterestExpense
3558000
CY2021 us-gaap Interest Expense
InterestExpense
3177000
CY2023 ubx Gain Loss On Warrant Liability Net Of Issuance Cost
GainLossOnWarrantLiabilityNetOfIssuanceCost
6215000
CY2022 ubx Gain Loss On Warrant Liability Net Of Issuance Cost
GainLossOnWarrantLiabilityNetOfIssuanceCost
16843000
CY2021 ubx Gain Loss On Warrant Liability Net Of Issuance Cost
GainLossOnWarrantLiabilityNetOfIssuanceCost
0
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1830000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1402000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-983000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39860000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-60725000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
227000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-207000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-49000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39633000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44676000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60774000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.7
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.7
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.88
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14773612
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14773612
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9494421
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9494421
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5581587
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5581587
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
82881000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1795000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
347000
CY2021 ubx Common Stock Issued To Third Parties Value
CommonStockIssuedToThirdPartiesValue
1457000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11553000
CY2021 ubx Repayment Of Promissory Note From Related Party From Purchase Of Common Stock
RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock
210000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-60725000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
142000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9379000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-207000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56084000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
116000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7419000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
227000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39860000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28398000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39860000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-60725000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1182000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2180000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2880000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
705000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1318000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
813000
CY2023 ubx Gain Loss On Extinguishment Of Debt Upon Paydown Of Principal
GainLossOnExtinguishmentOfDebtUponPaydownOfPrincipal
-491000
CY2022 ubx Gain Loss On Extinguishment Of Debt Upon Paydown Of Principal
GainLossOnExtinguishmentOfDebtUponPaydownOfPrincipal
0
CY2021 ubx Gain Loss On Extinguishment Of Debt Upon Paydown Of Principal
GainLossOnExtinguishmentOfDebtUponPaydownOfPrincipal
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
123000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1503000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
276000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1043000
CY2023 us-gaap Other Noncash Expense
OtherNoncashExpense
0
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
0
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
825000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
114000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
7419000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9379000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
11553000
CY2023 ubx Common Stock Issued To Third Parties
CommonStockIssuedToThirdParties
0
CY2022 ubx Common Stock Issued To Third Parties
CommonStockIssuedToThirdParties
0
CY2021 ubx Common Stock Issued To Third Parties
CommonStockIssuedToThirdParties
1457000
CY2023 ubx Non Cash Rent Expenses
NonCashRentExpenses
-1072000
CY2022 ubx Non Cash Rent Expenses
NonCashRentExpenses
-2136000
CY2021 ubx Non Cash Rent Expenses
NonCashRentExpenses
-2152000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5602000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
6215000
CY2022 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
16843000
CY2021 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
0
CY2023 ubx Extinguishment Loss And Issuance Costs On Warrant
ExtinguishmentLossAndIssuanceCostsOnWarrant
668000
CY2022 ubx Extinguishment Loss And Issuance Costs On Warrant
ExtinguishmentLossAndIssuanceCostsOnWarrant
0
CY2021 ubx Extinguishment Loss And Issuance Costs On Warrant
ExtinguishmentLossAndIssuanceCostsOnWarrant
0
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1664000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-138000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1288000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
74000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-39000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
91000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-410000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-573000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1180000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1008000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1327000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1063000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
26000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1131000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-23000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
24000
CY2023 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
963000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
216000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37088000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52414000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45060000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28609000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
98827000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
81492000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
89000000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
74000000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
121000000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
378000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60495000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24545000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39313000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20000000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1563000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1967000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023 ubx Proceeds From Repayment Of Employee Promissory Notes
ProceedsFromRepaymentOfEmployeePromissoryNotes
0
CY2022 ubx Proceeds From Repayment Of Employee Promissory Notes
ProceedsFromRepaymentOfEmployeePromissoryNotes
0
CY2021 ubx Proceeds From Repayment Of Employee Promissory Notes
ProceedsFromRepaymentOfEmployeePromissoryNotes
210000
CY2023 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
0
CY2022 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
0
CY2021 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
1784000
CY2023 ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
116000
CY2022 ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
142000
CY2021 ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
347000
CY2023 ubx Current Portion Of Long Term Debt Arrangement
CurrentPortionOfLongTermDebtArrangement
0
CY2022 ubx Current Portion Of Long Term Debt Arrangement
CurrentPortionOfLongTermDebtArrangement
0
CY2021 ubx Current Portion Of Long Term Debt Arrangement
CurrentPortionOfLongTermDebtArrangement
68000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16340000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56240000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20845000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7067000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20719000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15098000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19253000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20699000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1969000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2204000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2370000
CY2023 ubx Issuance Of Common Shares In Payment Of Debt
IssuanceOfCommonSharesInPaymentOfDebt
0
CY2022 ubx Issuance Of Common Shares In Payment Of Debt
IssuanceOfCommonSharesInPaymentOfDebt
3179000
CY2021 ubx Issuance Of Common Shares In Payment Of Debt
IssuanceOfCommonSharesInPaymentOfDebt
2704000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-484400000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39900000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37100000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q4 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
43200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12736000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82059000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1740000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96535000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7825000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19042000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2022Q4 us-gaap Assets
Assets
124350000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1790000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3020000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5334000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9476000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19620000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26991000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10891000
CY2022Q4 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
10764000
CY2022Q4 us-gaap Liabilities
Liabilities
68266000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14215302
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14215302
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
500827000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-251000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444493000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56084000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124350000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36859000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20949000
CY2022 us-gaap Operating Expenses
OperatingExpenses
57808000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-57572000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1220000
CY2022 us-gaap Interest Expense
InterestExpense
3558000
CY2022 ubx Gain Loss On Warrant Liability Net Of Issuance Cost
GainLossOnWarrantLiabilityNetOfIssuanceCost
16843000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1402000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-207000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44676000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9494421
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9494421
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
142000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9379000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-207000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56084000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2180000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1318000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
276000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9379000
CY2022 ubx Non Cash Rent Expenses
NonCashRentExpenses
-2136000
CY2022 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
16843000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-138000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-39000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1008000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
26000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-23000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52414000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
98827000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
74000000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
378000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24545000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1967000
CY2022 ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
142000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56240000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20719000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2204000
CY2022 ubx Issuance Of Common Stock In Payment Of Debt
IssuanceOfCommonStockInPaymentOfDebt
3179000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use asset and lease liabilities, embedded derivatives and stock-based compensation. Actual results could differ from such estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, derivatives liabilities are highly volatile and sensitive to changes in the market price of the Company’s common stock. Because liability-classified financial instruments are initially and subsequently carried at fair value, the Company’s financial results will reflect the volatility in these estimate and assumption changes. Changes in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimated fair value are recognized as a component of "Other expense, net" in the Statements of Operations and Comprehensive Loss.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19803000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12736000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32905000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
896000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
896000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20699000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s investment policy limits investments in marketable securities to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> off-balance sheet concentrations of credit risk.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2023 and 2022, the Company had no off-balance sheet concentrations of credit risk.
CY2022Q4 ubx Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
0
CY2023Q4 ubx Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
0
CY2023 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#222222;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Embedded Derivatives of the Loan Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures derivative liability related to debt at fair value. Estimated fair value of the derivative liability related to debt, initially measured and recorded on the date of the amendment of the loan and security agreement, is considered to be a Level 3 instrument. The fair value of the derivative liability related to debt is based on the term loan principal, the date of maturity, the contractual term loan interest rate, the convertible discount factor, and the selected discount rate of the loan. The derivative liability related to debt is recorded at fair value at the end of each reporting period with changes in estimated fair values recognized as a component of "Other expense, net" in the Statements of Operations and Comprehensive Loss.</span></p>
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
40172000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
40147000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
87394000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
259000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
87142000
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 ubx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
415000
CY2022Q4 ubx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
378000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
541000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
710000
CY2023Q4 ubx Tax Credit Receivable Current
TaxCreditReceivableCurrent
1493000
CY2022Q4 ubx Tax Credit Receivable Current
TaxCreditReceivableCurrent
0
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
84000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
235000
CY2023Q4 ubx Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
871000
CY2022Q4 ubx Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
417000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3404000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1740000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14343000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20579000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9261000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12754000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5082000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7825000
CY2023 us-gaap Depreciation
Depreciation
1200000
CY2023 us-gaap Lease Cost
LeaseCost
499000
CY2022 us-gaap Lease Cost
LeaseCost
1265000
CY2021 us-gaap Lease Cost
LeaseCost
3412000
CY2022 us-gaap Depreciation
Depreciation
2200000
CY2021 us-gaap Depreciation
Depreciation
2900000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3451000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3100000
CY2023Q4 ubx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
839000
CY2022Q4 ubx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1623000
CY2023Q4 ubx Liability Related To Early Exercise Shares
LiabilityRelatedToEarlyExerciseShares
10000
CY2022Q4 ubx Liability Related To Early Exercise Shares
LiabilityRelatedToEarlyExerciseShares
10000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
601000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4619000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5334000
CY2023Q4 ubx Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
1500000
CY2022Q4 ubx Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
0
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
3739000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
4264000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
4357000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
748000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1318000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
1633000
CY2023 us-gaap Sublease Income
SubleaseIncome
3988000
CY2022 us-gaap Sublease Income
SubleaseIncome
4317000
CY2021 us-gaap Sublease Income
SubleaseIncome
2578000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
4810000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6283000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
6653000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4964000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5123000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5287000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5457000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5633000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5801000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
32265000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5275000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26990000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3451000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23539000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
5600000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
4000000
CY2023 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1600000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
-500000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16784969
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16784969
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14215302
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14215302
CY2019Q2 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000
CY2022Q1 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
125000000
CY2022Q4 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000
CY2022Q1 ubx Restructuring And Related Activities Initiation Month And Year
RestructuringAndRelatedActivitiesInitiationMonthAndYear
2022-02
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
29
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
us-gaap Severance Costs1
SeveranceCosts1
1900000
CY2022 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
1700000
CY2023Q2 ubx Restructuring And Related Activities Initiation Month And Year
RestructuringAndRelatedActivitiesInitiationMonthAndYear
2023-05
CY2023Q2 ubx Restructuring And Related Cost Expected Number Of Employees Eliminated
RestructuringAndRelatedCostExpectedNumberOfEmployeesEliminated
9
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.29
CY2023Q2 ubx Restructuring And Related Cost Expected Number Of Employees Eliminated
RestructuringAndRelatedCostExpectedNumberOfEmployeesEliminated
6
CY2023Q2 ubx Restructuring And Related Cost Expected Number Of Employees Eliminated
RestructuringAndRelatedCostExpectedNumberOfEmployeesEliminated
3
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
68838
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1609938
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.51
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
251000
CY2023 ubx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Added In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAddedInPeriod
1010831
CY2023 ubx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
446200
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
446200
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.79
CY2023 ubx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Canceled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceledInPeriod
153367
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
142793
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.96
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
786836
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1913345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.23
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1179366
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
20.51
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1913345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.23
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.79
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.11
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
320000
CY2022 ubx Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward
0
CY2023 ubx Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M14D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9411
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9892
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8622
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9317
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.857
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.885
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0336
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0413
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0241
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0401
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0108
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7419000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9379000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11553000
CY2023Q2 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2023-05-04
CY2023 ubx Number Of Terminated Employees With Consulting Agreements
NumberOfTerminatedEmployeesWithConsultingAgreements
5
CY2023 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
9
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
300000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39860000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44469000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-60725000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14773612
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14773612
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9494421
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9494421
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5581587
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5581587
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.7
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.7
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.88
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8562447
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8254118
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1083900
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.09
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.091
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2023 ubx Effective Income Tax Rate Reconciliation Warrant Activity Percent
EffectiveIncomeTaxRateReconciliationWarrantActivityPercent
0.028
CY2022 ubx Effective Income Tax Rate Reconciliation Warrant Activity Percent
EffectiveIncomeTaxRateReconciliationWarrantActivityPercent
0.073
CY2021 ubx Effective Income Tax Rate Reconciliation Warrant Activity Percent
EffectiveIncomeTaxRateReconciliationWarrantActivityPercent
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.066
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.016
CY2023 ubx Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment
0.018
CY2022 ubx Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment
0.029
CY2021 ubx Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment
0.032
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.088
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.047
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.038
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.075
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.042
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.237
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.301
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.262
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81094000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
73322000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9552000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8646000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5078000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4589000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
320000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
587000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1343000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5329000
CY2023Q4 ubx Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
10117000
CY2022Q4 ubx Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
6624000
CY2023Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0
CY2022Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
12000
CY2023Q4 ubx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
6280000
CY2022Q4 ubx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
6908000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
113784000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
106017000
CY2023Q4 ubx Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
3041000
CY2022Q4 ubx Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
4371000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1033000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1299000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4074000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5670000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
109710000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
100347000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13400000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17605000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13221000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7142000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
84000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4395000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3457000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
232000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
11000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2622000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17457000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17605000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13221000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22576000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
76364000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3084000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
550000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
102574000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8202000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19515000
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4980000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2022Q3 us-gaap Assets
Assets
136243000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2444000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2961000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5321000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
6776000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17502000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27792000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13262000
CY2022Q3 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
16633000
CY2022Q3 us-gaap Liabilities
Liabilities
75189000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14036249
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14036249
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
498401000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-275000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437073000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
61054000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136243000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22972000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
60420000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2989000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
86381000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7496000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18557000
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
896000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2023Q1 us-gaap Assets
Assets
114255000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1470000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1983000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5343000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
13062000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21858000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26150000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7619000
CY2023Q1 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
5273000
CY2023Q1 us-gaap Liabilities
Liabilities
60900000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14359214
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14359214
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503276000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-150000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-449772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53355000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114255000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19118000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49974000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3874000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
72966000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7181000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18061000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1899000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000
CY2023Q2 us-gaap Assets
Assets
101008000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1449000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1652000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5417000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13623000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22141000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25297000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4067000
CY2023Q2 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
8734000
CY2023Q2 us-gaap Liabilities
Liabilities
60239000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14595477
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14595477
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
506132000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-136000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-465228000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40769000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101008000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7876000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
38063000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3599000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
49538000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5314000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13522000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2023Q3 us-gaap Assets
Assets
69270000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1149000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2226000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5258000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8633000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24431000
CY2023Q3 ubx Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
8481000
CY2023Q3 us-gaap Liabilities
Liabilities
41545000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14614890
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14614890
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
507789000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-55000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-480010000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
27725000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69270000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9086000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29100000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4922000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15669000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
14008000
us-gaap Operating Expenses
OperatingExpenses
22407000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11848000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22407000
us-gaap Operating Expenses
OperatingExpenses
44769000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14008000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44533000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
329000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
416000
CY2022Q3 us-gaap Interest Expense
InterestExpense
866000
us-gaap Interest Expense
InterestExpense
2568000
CY2022Q3 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
10974000
ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
10974000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1426000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1336000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4997000
us-gaap Net Income Loss
NetIncomeLoss
-37047000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-88000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-231000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5085000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37278000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.5
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.67
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10072077
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10072077
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7928729
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7928729
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5760000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4798000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
10558000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10558000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
855000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1002000
CY2023Q1 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
5491000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5279000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
101000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5178000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14312887
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14312887
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6435000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12195000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5413000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10212000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11848000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
805000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1660000
CY2023Q2 us-gaap Interest Expense
InterestExpense
883000
us-gaap Interest Expense
InterestExpense
1885000
CY2023Q2 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-3461000
ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2030000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-69000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15456000
us-gaap Net Income Loss
NetIncomeLoss
-20735000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
115000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15442000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20620000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14425775
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14425775
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14369643
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14369643
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4632000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16828000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4347000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14560000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5602000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5602000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14581000
us-gaap Operating Expenses
OperatingExpenses
36990000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14581000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36990000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
689000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2349000
CY2023Q3 us-gaap Interest Expense
InterestExpense
566000
us-gaap Interest Expense
InterestExpense
2451000
CY2023Q3 ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
253000
ubx Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2283000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-577000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-711000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14782000
us-gaap Net Income Loss
NetIncomeLoss
-35520000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
81000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
196000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14701000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35324000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14598218
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14598218
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14446672
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14446672
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
39931000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2210000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-88000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4997000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
61054000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56084000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2175000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
101000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5279000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53355000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53355000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
91000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2247000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15456000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40769000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40769000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1705000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
81000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14782000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
27725000
us-gaap Net Income Loss
NetIncomeLoss
-37047000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1771000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
989000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-155000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
247000
us-gaap Share Based Compensation
ShareBasedCompensation
7120000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-1891000
ubx Gain Loss On Warrant Liability Net Of Issuance Costs
GainLossOnWarrantLiabilityNetOfIssuanceCosts
10974000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1205000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
459000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1067000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
96000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-23000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42048000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
86567000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
62000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
272000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24354000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1965000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
125000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56073000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10329000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24022000
us-gaap Interest Paid Net
InterestPaidNet
1577000
ubx Issuance Of Common Shares In Payment Of Debt
IssuanceOfCommonSharesInPaymentOfDebt
3179000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22576000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1446000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24022000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5279000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
329000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
314000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
433000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2175000
CY2023Q1 ubx Non Cash Rent Expenses
NonCashRentExpenses
-270000
CY2023Q1 ubx Gain Loss On Warrant Liability Net Of Issuance Costs
GainLossOnWarrantLiabilityNetOfIssuanceCosts
5491000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1249000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-23000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-320000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1037000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-78000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11316000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5973000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27251000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21278000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
274000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10236000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23868000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
680000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22972000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
896000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23868000
us-gaap Net Income Loss
NetIncomeLoss
-20735000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
643000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
557000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
831000
us-gaap Share Based Compensation
ShareBasedCompensation
4422000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-540000
ubx Gain Loss On Warrant Liability Net Of Issuance Costs
GainLossOnWarrantLiabilityNetOfIssuanceCosts
2030000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2134000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-341000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1368000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-89000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22399000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21868000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31132000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3234000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
91000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2351000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6382000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20014000
us-gaap Interest Paid Net
InterestPaidNet
1362000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19118000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
896000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20014000
us-gaap Net Income Loss
NetIncomeLoss
-35520000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
951000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
705000
ubx Gain Loss On Extinguishment Of Debt Upon Paydown Of Principal
GainLossOnExtinguishmentOfDebtUponPaydownOfPrincipal
-491000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1199000
us-gaap Share Based Compensation
ShareBasedCompensation
6127000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-811000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5602000
ubx Gain Loss On Warrant Liability Net Of Issuance Costs
GainLossOnWarrantLiabilityNetOfIssuanceCosts
2283000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1858000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-52000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-642000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-793000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-335000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29513000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28609000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
74000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45381000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1563000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
91000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20728000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4860000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8772000
us-gaap Interest Paid Net
InterestPaidNet
1969000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7876000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
896000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8772000

Files In Submission

Name View Source Status
0000950170-24-044237-index-headers.html Edgar Link pending
0000950170-24-044237-index.html Edgar Link pending
0000950170-24-044237.txt Edgar Link pending
0000950170-24-044237-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img59732416_0.jpg Edgar Link pending
img59732416_1.jpg Edgar Link pending
img59732416_2.jpg Edgar Link pending
img59732416_3.jpg Edgar Link pending
img59732416_4.jpg Edgar Link pending
img59732416_5.jpg Edgar Link pending
img59732416_6.jpg Edgar Link pending
img59732416_7.jpg Edgar Link pending
img59732416_8.jpg Edgar Link pending
img59732416_9.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-20231231.htm Edgar Link pending
ubx-20231231.xsd Edgar Link pending
ubx-ex10_41.htm Edgar Link pending
ubx-ex23_1.htm Edgar Link pending
ubx-ex31_1.htm Edgar Link pending
ubx-ex31_2.htm Edgar Link pending
ubx-ex32_1.htm Edgar Link pending
ubx-ex3_3.htm Edgar Link pending
ubx-ex97_1.htm Edgar Link pending
ubx-20231231_htm.xml Edgar Link completed